224 related articles for article (PubMed ID: 25123575)
21. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
[TBL] [Abstract][Full Text] [Related]
22. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
[TBL] [Abstract][Full Text] [Related]
24. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
[TBL] [Abstract][Full Text] [Related]
25. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
26. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
[TBL] [Abstract][Full Text] [Related]
27. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
28. [Clinical research progress of T-DM1 in breast cancer].
Li LX; Ma F
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
30. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
[TBL] [Abstract][Full Text] [Related]
32. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
Diéras V; Bachelot T
Target Oncol; 2014 Jun; 9(2):111-22. PubMed ID: 23852665
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
34. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
[TBL] [Abstract][Full Text] [Related]
35. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
37. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
[TBL] [Abstract][Full Text] [Related]
39. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.
Bighin C; Pronzato P; Del Mastro L
Future Oncol; 2013 Jul; 9(7):955-7. PubMed ID: 23837759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
